ACHILLION PHARMACEUTICALS IN's ticker is ACHN and the CUSIP is 00448Q201. A total of 106 filers reported holding ACHILLION PHARMACEUTICALS IN in Q3 2013. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $24,802,000 | +242.1% | 4,113,556 | +104.3% | 0.00% | +50.0% |
| Q3 2019 | $7,249,000 | +45.4% | 2,013,693 | +8.3% | 0.00% | +100.0% |
| Q2 2019 | $4,985,000 | -3.7% | 1,860,151 | +6.4% | 0.00% | 0.0% |
| Q1 2019 | $5,174,000 | +5.2% | 1,748,069 | -43.5% | 0.00% | 0.0% |
| Q4 2018 | $4,918,000 | -8.2% | 3,094,008 | +112.6% | 0.00% | -50.0% |
| Q3 2018 | $5,356,000 | +31.7% | 1,455,658 | +1.2% | 0.00% | +100.0% |
| Q2 2018 | $4,068,000 | -15.3% | 1,437,697 | +11.1% | 0.00% | -50.0% |
| Q1 2018 | $4,802,000 | +58.2% | 1,294,347 | +22.8% | 0.00% | +100.0% |
| Q4 2017 | $3,035,000 | -35.2% | 1,053,860 | +1.1% | 0.00% | -50.0% |
| Q3 2017 | $4,682,000 | -4.9% | 1,042,866 | -2.8% | 0.00% | 0.0% |
| Q2 2017 | $4,925,000 | +16.7% | 1,073,029 | +7.0% | 0.00% | 0.0% |
| Q1 2017 | $4,221,000 | +12.2% | 1,002,784 | +10.1% | 0.00% | 0.0% |
| Q4 2016 | $3,761,000 | -52.2% | 910,741 | -6.3% | 0.00% | -50.0% |
| Q3 2016 | $7,875,000 | +14.7% | 972,231 | +10.4% | 0.00% | 0.0% |
| Q2 2016 | $6,865,000 | +11.5% | 880,254 | +10.4% | 0.00% | +33.3% |
| Q1 2016 | $6,156,000 | -25.7% | 797,518 | +3.9% | 0.00% | -40.0% |
| Q4 2015 | $8,281,000 | +66.2% | 767,495 | +6.4% | 0.01% | +66.7% |
| Q3 2015 | $4,984,000 | -18.3% | 721,274 | +4.7% | 0.00% | 0.0% |
| Q2 2015 | $6,100,000 | -5.5% | 688,632 | +5.2% | 0.00% | -25.0% |
| Q1 2015 | $6,452,000 | -5.0% | 654,385 | +18.0% | 0.00% | 0.0% |
| Q4 2014 | $6,791,000 | +27.6% | 554,419 | +3.9% | 0.00% | +33.3% |
| Q3 2014 | $5,324,000 | +39.9% | 533,532 | +6.1% | 0.00% | +50.0% |
| Q2 2014 | $3,806,000 | +157.2% | 502,892 | +11.7% | 0.00% | +100.0% |
| Q1 2014 | $1,480,000 | +8.9% | 450,043 | +9.9% | 0.00% | 0.0% |
| Q4 2013 | $1,359,000 | +12.7% | 409,495 | +2.5% | 0.00% | 0.0% |
| Q3 2013 | $1,206,000 | -53.7% | 399,478 | +25.4% | 0.00% | -50.0% |
| Q2 2013 | $2,605,000 | – | 318,453 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 13,633,220 | $57,396,000 | 7.04% |
| HealthInvest Partners AB | 497,807 | $2,096,000 | 3.21% |
| BVF INC/IL | 3,285,400 | $13,832,000 | 2.35% |
| EMORY UNIVERSITY | 486,438 | $2,048,000 | 1.93% |
| Marcus Capital, LLC | 69,400 | $1,751,000 | 1.63% |
| DAFNA Capital Management LLC | 196,500 | $827,000 | 0.70% |
| Orbimed Advisors | 13,107,200 | $55,181,000 | 0.62% |
| Rock Springs Capital Management LP | 1,500,000 | $6,315,000 | 0.36% |
| Spark Investment Management LLC | 710,100 | $2,989,000 | 0.19% |
| TURNER INVESTMENTS LLC | 65,420 | $275,000 | 0.18% |